Press release
Focal Segmental Glomerulosclerosis Therapeutics Market Size in the 7MM was ~USD 734 million in 2022, is expected to grow by 2034, and estimated DelveInsight
Discover Key Insights into the Focal Segmental Glomerulosclerosis Market with DelveInsight's In-Depth Report @ Focal Segmental Glomerulosclerosis Market Size [https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Focal Segmental Glomerulosclerosis Market Report
* In December 2024:- Astellas Pharma Global Development, Inc.- The purpose of this study was to assess the efficacy of the bleselumab regimen (basiliximab induction, tacrolimus, steroids and bleselumab) compared with the Standard of Care (SOC) regimen (basiliximab induction, tacrolimus, steroids and mycophenolate mofetil [MMF]) in the prevention of recurrent Focal Segmental Glomerulosclerosis (rFSGS) defined as nephrotic range proteinuria with protein-creatinine ratio ( greater than or equal to 3.0 g/g) through 3 months post-transplant. Death, graft loss or lost to follow-up were imputed as rFSGS.
* In December 2024:- Sanofi- A Parallel-group Treatment, Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Umbrella Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, and Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD).
* The overall count of individuals diagnosed with Focal Segmental Glomerulosclerosis in the United States was approximately 26 million in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
* Among the 7MM, Japan accounted for the highest number of Focal Segmental Glomerulosclerosis diagnosed cases of around 8 million cases in 2022. Forecasts indicate a projected increase in the cases during the period (2023-2034).
* Among EU4 and the UK, Germany had the highest Focal Segmental Glomerulosclerosis diagnosed prevalent population, with about 5 million cases, followed by France and Italy in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
* In 2022, DelveInsight's analysis of Focal Segmental Glomerulosclerosis gender-specific diagnosed prevalent cases within the 7MM indicated an approximate distribution of 40% in males and 60% in females.
* The leading Focal Segmental Glomerulosclerosis Companies such as Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Company and others.
* Promising Focal Segmental Glomerulosclerosis Therapies such as DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others.
Stay ahead in the Focal Segmental Glomerulosclerosis Therapeutics Market with DelveInsight's Strategic Report @ Focal Segmental Glomerulosclerosis Market Outlook [https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Focal Segmental Glomerulosclerosis Epidemiology Segmentation in the 7MM
* Total Focal Segmental Glomerulosclerosis Diagnosed Prevalent Cases
* Focal Segmental Glomerulosclerosis Gender-specific Cases
* Diagnosed Prevalent Cases
* Focal Segmental Glomerulosclerosis Age-specific Diagnosed Prevalent Cases
* Focal Segmental Glomerulosclerosis Comorbodity-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Focal Segmental Glomerulosclerosis Epidemiology trends @ Focal Segmental Glomerulosclerosis Prevalence [https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Focal Segmental Glomerulosclerosis Marketed Drugs
* LEQVIO (Inclisiran): Novartis Pharmaceuticals Corporation
LEQVIO (Inclisiran) is a sole small-interfering RNA (siRNA) therapy designed to lower LDL cholesterol. The drug utilizes the RNA interference mechanism and directs the catalytic breakdown of mRNA for PCSK9. This increases LDL-C receptor recycling and expression on the hepatocyte cell surface, which increases LDL-C uptake and lowers LDL-C levels in the circulation. LEQVIO, the sole approved FSGS treatment in United States and Europe with an active patent, dominates the FSGS treatment landscape, immune to biosimilar competition.
Focal Segmental Glomerulosclerosis Emerging Drugs
* Olpasiran (AMG 890): Amgen Inc.
Olpasiran (AMG 890) is a small interfering RNA (siRNA) that lowers lipoprotein(a). It is being investigated for treating FSGS; the drug is administered subcutaneously as a solution. Olpasiran is currently in Phase III clinical trial in participants with FSGS and elevated lipoprotein (a). The absence of approved alternatives highlights the potential for Olpasiran to contribute significantly to the expansion of the FSGS treatment market.
Focal Segmental Glomerulosclerosis Market Outlook
Focal Segmental Glomerulosclerosis (FSGS), encompassing diverse conditions like CAD, PAD, and cerebrovascular disease, all rooted in atherosclerosis. FSGS is influenced by genetic predisposition, lifestyle factors, and comorbidities. Strategies vary depending on the severity of the disease, aiming to curb FSGS. Treatment for FSGS starts with a change in lifestyle that includes stress management, regular exercise, dietary adjustments, and quitting smoking. Their potential to supplement pharmaceutical therapies and effectively lower cardiovascular risk factors is highlighted by a thorough examination of their influence on patient outcomes.
Get In-Depth Knowledge on Focal Segmental Glomerulosclerosis Market Trends and Forecasts with DelveInsight @ Focal Segmental Glomerulosclerosis Treatment Market [https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Focal Segmental Glomerulosclerosis Treatment Market
As the Focal Segmental Glomerulosclerosis Treatment Market Landscape evolves, the emergence of Olpasiran in a Phase III trial brings hope for a targeted therapeutic option. The projected introduction of Olpasiran for FSGS is anticipated to propel the overall FSGS market in the 7MM, potentially reaching nearly USD 837 million by 2034.
Scope of the Focal Segmental Glomerulosclerosis Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* Focal Segmental Glomerulosclerosis Companies- Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Company and others.
* Focal Segmental Glomerulosclerosis Therapies- DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others.
* Focal Segmental Glomerulosclerosis Therapeutic Assessment: Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies
* Focal Segmental Glomerulosclerosis Market Dynamics: Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers
* Focal Segmental Glomerulosclerosis Unmet Needs, KOL's views, Analyst's views, Focal Segmental Glomerulosclerosis Market Access and Reimbursement
Unlock Strategic Insights with DelveInsight's Comprehensive Focal Segmental Glomerulosclerosis Market Report @ Focal Segmental Glomerulosclerosis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1 Key Insights
2 Report Introduction
3 Focal Segmental Glomerulosclerosis (FSGS) Market Overview by Therapies
4 Methodology of FSGS Epidemiology and Market
5 Executive Summary of Focal Segmental Glomerulosclerosis (FSGS)
6 Key Events
7 Disease Background and Overview: FSGS
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Drugs
11 Emerging Drugs
12 FSGS: Market Analysis
13 Key Opinion Leaders' Views
14 SWOT Analysis
15 Unmet Needs
16 Market Access and Reimbursement
17 Appendix
18 Report Methodology
19 DelveInsight Capabilities
20 Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=focal-segmental-glomerulosclerosis-therapeutics-market-size-in-the-7mm-was-usd-734-million-in-2022-is-expected-to-grow-by-2034-and-estimated-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Focal Segmental Glomerulosclerosis Therapeutics Market Size in the 7MM was ~USD 734 million in 2022, is expected to grow by 2034, and estimated DelveInsight here
News-ID: 3803243 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Focal
Focal Epilepsy Market New Product Development & Latest Trends
Introduction
Focal epilepsy, the most common form of epilepsy worldwide, originates in specific regions of the brain and often presents with partial seizures. Affecting millions of people globally, focal epilepsy remains a pressing neurological challenge with significant clinical and economic impact. Increasing diagnosis rates, technological advances in imaging and neurostimulation, and new pharmacological approaches are fueling rapid changes in the treatment landscape.
As healthcare systems place greater emphasis on effective long-term management…
Focal Segmental Glomerulosclerosis Market Size Report 2024
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Focal Segmental Glomerulosclerosis Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $22.41 billion In…
3D FOCAL LINES SPATULA TECHNOLOGY for SYGMALIFT
Focal Ultrasounds in three-dimensional (3D) technology expand to the Face Lifting and V Facing. This innovation is able to treat volume that contains every conceivable plane (X, Y, Z angles) within the region of interest such as Double Chin or Cheeks.
While there is no doubt that there are advantages to volume treatment in 2.5 Seconds only, it delivers more power and add clinical benefit to target submental and jawlines…
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Pipeline Analysis 2018
Focal segmental glomerulosclerosis (FSGS) is a glomerular disease, which is characterized by scarring or sclerosis in the kidney. Scarring damages the limited number of glomeruli in the initial stages. It is more common in males than in females, anad is very common in African American population.
Download the sample report @ https://www.pharmaproff.com/request-sample/1090
FSGS can be caused by many diseases like diabetes, sickle cell disease, and HIV infection. It is categorized into two…
Focal Segmental Glomerulosclerosis (FSGS) Market Report 2018: Segmentation by Di …
Global Focal Segmental Glomerulosclerosis (FSGS) market research report provides company profile for Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth…
Africa Energy Week – Three Different Focal Points, One Conference
Africa’s development in oil and gas has significantly increased over the last few years; Ghana’s Jubilee field, first discovered in 2007, is now producing 70,000 barrels a day and may climb to 120,000 by the end of the year. With much of its oil for export, the country’s economic growth is climbing at a rapid rate, and many are looking to follow suit. Local content has since been a hot…
